PFC Capital Group Inc. Trims Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

PFC Capital Group Inc. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,125 shares of the medical research company’s stock after selling 80 shares during the quarter. PFC Capital Group Inc.’s holdings in Thermo Fisher Scientific were worth $585,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in TMO. Legacy Investment Solutions LLC bought a new position in Thermo Fisher Scientific in the third quarter worth approximately $26,000. Barrett & Company Inc. purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $28,000. FPC Investment Advisory Inc. acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $28,000. Pillar Financial Advisors LLC acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $29,000. Finally, Missouri Trust & Investment Co purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $29,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $498.05 on Tuesday. The company has a market cap of $187.89 billion, a price-to-earnings ratio of 30.13, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 52 week low of $484.27 and a 52 week high of $627.88. The company has a fifty day simple moving average of $540.37 and a two-hundred day simple moving average of $551.02.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a $0.43 dividend. The ex-dividend date is Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.41%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TMO. Citigroup reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. UBS Group upped their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective on the stock in a report on Friday, January 10th. Royal Bank of Canada set a $693.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 31st. Finally, StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $653.23.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares in the company, valued at $59,506,950.58. This represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 23,900 shares of company stock valued at $13,106,062. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.